{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-25-005877","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.275276+00:00","generated_at":"2026-05-21T23:21:15.607532+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tonix Q1 net loss $16.8M; cash $131.7M; PDUFA date Aug 15 for TNX-102 SL","bullets":["Net loss $16.8M ($2.84/share) vs $14.9M ($535.72/share) in Q1 2024; product revenue $2.4M.","Cash and equivalents $131.7M as of March 31, 2025; cash runway into Q2 2026.","FDA PDUFA goal date Aug 15, 2025 for TNX-102 SL for fibromyalgia; if approved, first new drug in >15 years.","Positive Phase 1 results for TNX-1500 anti-CD40L mAb; plans for Phase 2 in kidney transplant.","Discontinued Phase 2 CATALYST study of TNX-1300 due to slow enrollment; not safety/efficacy."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-25-005877","json":"https://secwatch.observer/filing/0001999371-25-005877.json","markdown":"https://secwatch.observer/filing/0001999371-25-005877.md","text":"https://secwatch.observer/filing/0001999371-25-005877.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125005877/0001999371-25-005877-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125005877/tnxp-8k_051225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:21:15.607532+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}